Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · IEX Real-Time Price · USD
18.93
-1.98 (-9.47%)
At close: Jul 2, 2024, 4:00 PM
17.86
-1.07 (-5.65%)
After-hours: Jul 2, 2024, 6:31 PM EDT
Nurix Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Nurix Therapeutics stock have an average target of 25.1, with a low estimate of 10 and a high estimate of 35. The average target predicts an increase of 32.59% from the current stock price of 18.93.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NRIX stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 4 | 3 | 4 | 5 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 7 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $23 → $26 | Buy | Maintains | $23 → $26 | +37.35% | Jun 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $19 → $26 | Strong Buy | Maintains | $19 → $26 | +37.35% | Jun 18, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $30 → $31 | Buy | Maintains | $30 → $31 | +63.76% | Jun 17, 2024 |
| Needham | Needham | Strong Buy Reiterates $31 | Strong Buy | Reiterates | $31 | +63.76% | Jun 17, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $35 | Buy | Maintains | $35 | +84.89% | Jun 5, 2024 |
Financial Forecast
Revenue This Year
74.41M
from 76.99M
Decreased by -3.35%
Revenue Next Year
69.00M
from 74.41M
Decreased by -7.26%
EPS This Year
-2.91
from -2.65
EPS Next Year
-3.17
from -2.91
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 93.5M | 94.5M | 215.4M | 207.4M | 367.5M |
| Avg | 74.4M | 69.0M | 83.1M | 130.2M | 298.9M |
| Low | 55.9M | 32.7M | n/a | 73.8M | 214.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 21.5% | 27.0% | 212.1% | 149.7% | 182.2% |
| Avg | -3.4% | -7.3% | 20.4% | 56.8% | 129.5% |
| Low | -27.3% | -56.1% | - | -11.1% | 65.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.56 | -2.56 | -1.56 | -2.38 | -1.06 |
| Avg | -2.91 | -3.17 | -3.35 | -3.01 | -1.53 |
| Low | -3.46 | -4.83 | -4.85 | -3.29 | -1.75 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.